Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience

Clin Exp Dermatol. 2023 Mar 1;48(3):247-249. doi: 10.1093/ced/llac078.

Authors

Maddalena Napolitano¹, Luca Potestio², Katharina Hansel³, Rossella Marietti³, Ilaria Piscitelli², Gabriella Fabbrocini², Luca Stingeni³, Cataldo Patruno⁴

Affiliations

¹ Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
² Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II.
³ Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
⁴ Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

PMID: 36763761
DOI: 10.1093/ced/llac078

No abstract available

Publication types

Letter

MeSH terms

Adult
Dermatitis, Atopic*
Double-Blind Method
Heterocyclic Compounds, 3-Ring
Humans
Severity of Illness Index
Treatment Outcome

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring